When was FORMEL Skin founded?

FORMEL Skin was founded in 2020 and raised its 1st funding round 1 year after it was founded.

Where is FORMEL Skin located?

FORMEL Skin is headquartered in Berlin, Germany.

Which legal entities is FORMEL Skin associated with?

FORMEL Skin is associated with Formel Skin Derma GmbH and 2 others.

How many employees does FORMEL Skin have?

As of Apr 30, 2026, the latest employee count at FORMEL Skin is 80.

Is FORMEL Skin a funded company?

FORMEL Skin is a funded company, having raised a total of $39.7M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jan 10, 2021.

When was the latest funding round of FORMEL Skin?

FORMEL Skin's latest funding was a $***** Series A round on Dec 20, 2021, with participation from 5 investors.

Where does FORMEL Skin rank among its competitors?

FORMEL Skin ranks 340th amongst 2525 active competitors, of which 865 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Erasca, which secured $45M in Mar, 2024.

Who are the top competitors of FORMEL Skin?

FORMEL Skin's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics. Among them, Erasca secured the most recent funding round in March, 2024.

FORMEL Skin - 2026 Company Profile, Team, Funding, Competitors & Financials

FORMEL Skin is an acquired company based in Berlin (Germany), founded in 2020 by Anton Kononov and Florian Semler. It operates as a Manufacturer of dermatological skin care products. FORMEL Skin has raised $39.7M in funding from investors like Singular, Cherry Ventures and Heartcore Capital. The company has 2525 active competitors, including 865 funded and 619 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics.

Company Details

Website: www.formelskin.de/
Social
Email ID: *****@formelskin.de
Phone Number: +49 **********

Key Metrics

Founded Year

2020

Location

Berlin, Germany

Stage

Acquired

Total Funding

$39.7M in 2 rounds

Latest Funding Round

Series A, Dec 20, 2021, $*****

Investors

Singular & 10 more

Ranked

340^th among 2525 active competitors

Employee Count

80 as on Apr 30, 2026

Similar Companies

LEO Pharma & 146 more

Exit Details

Acquired by Manual (Dec 05, 2025)

View FORMEL Skin's full profile

FORMEL Skin is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count
Formel Skin Derma GmbH CIN: HRB216314 , Germany, Active	Mar 29, 2020	-	-
Formel Skin Derma GmbH CIN: F1103_HRB216314B , Germany, Active	Mar 30, 2020	-	-
TrueSkin GmbH CIN: HRB212398 , Germany, Active	Nov 20, 2019	-	-

FORMEL Skin got acquired by Manual on Dec 05, 2025.

Click here to take a look at FORMEL Skin's acquisition in detail

FORMEL Skin has raised a total funding of $39.7M over 2 rounds. Its first funding round was on Jan 10, 2021. Its latest funding round was a Series A round on Dec 20, 2021 for $*****. 5 investors participated in its latest round. FORMEL Skin has 8 institutional investors and 3 angel investors.

Here is the list of recent funding rounds of FORMEL Skin:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 20, 2021	6884769	Series A	9690890	6962751	1483194	9387419
Jan 10, 2021	4684235	Series A	5930252	2302701	Cherry Ventures & 2 more	4308299

Access funding benchmarks and valuations. Sign up today!

View details of FORMEL Skin's funding rounds and investors

The founders of FORMEL Skin are Anton Kononov and Florian Semler.

Here are the details of FORMEL Skin's key team members:

Anton Kononov: Co-Founder of FORMEL Skin. They are also an angel investor in 1 startup and serve on the board of 1 company.
Florian Semler: Co-Founder of FORMEL Skin. They serve on the board of 1 company.

FORMEL Skin's Board of Directors

FORMEL Skin's board has 2 active members. Anton Kononov and Florian Semler are part of team.

Here is the list of FORMEL Skin's board of directors:

Name	Type	Representing	Status	Duration
Anton Kononov	Team	-	Current	6y 0m
m{zzjri	Team	-	Past	2y 8m

View details of FORMEL Skin's Founder profiles and Board Members

FORMEL Skin's employee count trend

FORMEL Skin has 80 employees as of Apr 26. Here is FORMEL Skin's employee count trend over the years:

Uncover FORMEL Skin's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of FORMEL Skin include Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics. Here is the list of Top 10 competitors of FORMEL Skin, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, KKR & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
3rd	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	75/100
4th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	73/100
5th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
6th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	72/100
7th	LEO Pharma 1908, Copenhagen (Denmark), Late Stage	Developer of drugs for treating dermatology diseases	$560M	Nordic Capital	71/100
8th	Harbour BioMed 2016, Shanghai (China), Public	Developer of antibody therapeutics in immunology and oncology disease	$313M	GIC, Hudson Bay Capital & 19 others	71/100
9th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	70/100
10th	iTeos Therapeutics 2011, Cambridge (United States), Acquired	Developer of immunotherapy for treating cancer	$204M	RA Capital Management, Boxer Capital & 19 others	70/100
340th	FORMEL Skin 2020, Berlin (Germany), Acquired	Manufacturer of dermatological skin care products	$39.7M	Cherry Ventures, Vorwerk Ventures & 9 others	54/100